Galderma is claiming that the following patents protect their recently FDA Approved Brimonidine Gel known as Mirvaso. These patents are quoted in the Mirvaso Prescribing Information thus forming a public statement by Galderma to any would be competitors.
Note one patent is for using Mirvaso to treat the broken blood vessels of rosacea (telangiectasis). This possible benefit of Mirvaso has not been discussed as yet.
Massive R&D Effort
Reading these patents are interesting on a few levels. I find them revealing because it shows what Galderma asserts as the innovations behind their Mirvaso product.
There has been a significant R&D effort expended starting with Sansrosa and ending with Mirvaso now available as a prescription.
These patents will form the basis for Galderma protecting their intellectual property against generic competition. We can expect Brimonidine to only be available as rosacea treatment from Mirvaso and Galderma for many years into the future.
Mirvaso Patents
- 7,439,241. Compounds, formulations, and methods for treating or preventing rosacea.
A method of reducing redness associated with rosacea comprising topically administering a pharmaceutical composition comprising an effective amount of brimonidine or a pharmaceutically acceptable salt thereof to the site of the redness on the skin of a patient.
- 8,053,427. Brimonidine gel composition.
Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
- 8,163,725. Gel compositions and methods of use.
Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
- 8,231,885. Compounds, formulations, and methods for ameliorating telangiectasis.
The methods comprise topically applying a composition comprising an α-adrenergic receptor agonist to telangiectatic skin
- 8,410,102. Methods and compositions for treating or preventing erythema.
The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
- 8,426,410. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders.
A method of treating rosacea and the symptoms associated therewith, the method comprising topically administering to the skin of a patient in need of such treatment a composition comprising: a therapeutically effective amount of brimonidine or a pharmaceutically acceptable salt thereof;
